Hematology laboratory shift based on common terminology criteria in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily: Results from the 42-month BOLT study

Main Article Content

Michael Migden
University of Texas MD Anderson Cancer Center, Departments of Dermatology, Division of Internal Medicine, and Head and Neck Surgery, Division of Surgery

Alexander Guminski
Department of Oncology, Royal North Shore Hospital; Melanoma Institute Australia, The University of Sydney; Mater Hospital

Ralf Gutzmer
Skin Cancer Center Hannover, Department of Dermatology, Hannover Medical School

Carmen Loquai
Department of Dermatology, University Medical Center Mainz

Nicholas Squittieri
Sun Pharmaceutical Industries, Inc.

Peter Foley
Department of Dermatology, St Vincent’s Hospital Melbourne; The University of Melbourne; Skin Health Institute Inc.

Keywords

sonidegib, basal cell carcinoma, Hematology assessments, Hedgehog pathway inhibitor, Oncology, Advanced basal cell carcinoma

References

1. Cortes JE, et al. Cancer Treat Rev. 2019;76:41–50.

2. Kim JYS, et al. J Am Acad Dermatol. 2018;78(3):540–59.

3. Odomzo (sonidegib capsules). Full Prescribing Information. Sun Pharmaceutical Industries, Inc., Cranbury, NJ, USA.

4. European Medicines Agency. Summary of Product Characteristics, WC500188762. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002839/WC500192970.pdf.

5. Swissmedic, Authorization Number 65065, 2015. https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/authorisations/new-medicines/odomzo--200mg--kapseln--sonidegibum-.html.

6. Australian Government Department of Health, ARTG 292262. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2017-PI-02511-1&d=2018030216114622483.

7. Dummer R, et al. Br J Dermatol. 2020;182(6):1369–78.

8. Dummer R, et al. J Am Acad Dermatol. 2016;75(1):113–25.e115.

9. Lear JT, et al. J Eur Acad Dermatol Venereol. 2018;32(3):372–81.

10. Migden MR, et al. Lancet Oncol. 2015;16(6):716–28.

11. Health UDo, Services H. Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute. 2009;4(03).

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.180

Article Details

How to Cite
Migden, M., Guminski, A., Gutzmer, R., Loquai, C., Squittieri, N., & Foley, P. . (2023). Hematology laboratory shift based on common terminology criteria in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily: Results from the 42-month BOLT study. SKIN The Journal of Cutaneous Medicine, 7(2), s180. https://doi.org/10.25251/skin.7.supp.180
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 > >>